Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. (BOLT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BOLT · as of Sep 30, 2025
Ownership Breakdown
24
Institutional Holders
▼ 2 vs Q2
$4.28M
Total Inst. Value
▼ $820,296 vs Q2
1.92M
Shares Outstanding
freeFloat 81.61%
804,036
13F Shares Held
▼ 85,850 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BOLT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VIVO CAPITAL, LLC pharmaceutical preparations | 176.1K | 9.18% | 9.18% | $936.66M | Nov 14, 2025 | — held |
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 137.7K | 7.18% | 7.18% | $732.68M | Nov 14, 2025 | — held |
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC pharmaceutical preparations | 94.6K | 4.93% | 4.93% | $503.13M | Nov 13, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 66.9K | 3.49% | 3.49% | $355.80M | Nov 14, 2025 | ▼ 100.0K |
NAN FUNG GROUP HOLDINGS LTD pharmaceutical preparations | 58.3K | 3.04% | 3.04% | $310.41M | Nov 13, 2025 | — held |
SAMSARA BIOCAPITAL, LLC pharmaceutical preparations | 48.8K | 2.55% | 2.55% | $259.78M | Nov 14, 2025 | ▼ 3.6K |
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY pharmaceutical preparations | 36.0K | 1.88% | 1.88% | $191.40M | Nov 5, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 34.2K | 1.79% | 1.79% | $182.11M | Nov 7, 2025 | ▼ 24.3K |
PFIZER INC pharmaceutical preparations | 31.3K | 1.63% | 1.63% | $166.54M | Nov 13, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 28.6K | 1.49% | 1.49% | $152.28M | Nov 13, 2025 | ▲ 10.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
2
Increased
+12.7K shares3
New Positions
first time holders9
Decreased
−129.7K shares5
Sold Out
fully exitedNet shares change (top 50)
117.0K
+12.7K / −129.7K
Net new holders
-9
3 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BOLT insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Quinn William P. President, CEO and CFO | Jan 28, 2026 | Award | 20,000 | $6.71 | $134.2K | 20.0K | Form 4 ↗ |
Quinn William P. President, CEO and CFO | Dec 5, 2025 | Purchase | 125 | $4.61 | $575.875 | 2.3K | Form 4 ↗ |
Yonehiro Grant Chief Operating Officer | Jan 28, 2026 | Award | 10,000 | $6.71 | $67.1K | 10.0K | Form 4 ↗ |
Nemec Sarah Senior VP, Finance and PAO | Jan 28, 2026 | Award | 8,000 | $6.71 | $53.7K | 8.0K | Form 4 ↗ |
Nemec Sarah Senior VP, Finance and PAO | Dec 5, 2025 | Purchase | 125 | $4.61 | $575.875 | 1.4K | Form 4 ↗ |
Dupont Jakob director | Dec 12, 2025 | Award | 2,500 | $5.44 | $13.6K | 2.5K | Form 4 ↗ |
Dupont Jakob director | Dec 12, 2025 | Award | 1,100 | $5.44 | $6.0K | 1.1K | Form 4 ↗ |
Dupont Jakob director | Dec 12, 2025 | Award | 1,000 | $5.44 | $5.4K | 1.0K | Form 4 ↗ |
Dupont Jakob director | Dec 12, 2025 | Award | 849 | $5.44 | $4.6K | 849 | Form 4 ↗ |
Dupont Jakob director | Dec 12, 2025 | D-Return | 1,000 | $7.02 | $7.0K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Bolt Biotherapeutics, Inc. (BOLT) is primarily owned by institutional investors, who hold approximately 41.8% of total shares outstanding. Company insiders own approximately 18.39%, while retail and public investors account for the remaining 39.77%.
The largest institutional shareholder of Bolt Biotherapeutics, Inc. is VIVO CAPITAL, LLC, holding approximately 176,064 shares — equal to 9.18% of outstanding shares — as of September 30, 2025.
A total of 24 institutional investors currently hold BOLT stock, with a combined institutional value of approximately $4,277,487 as of the most recent 13F filing period.
Frequently asked questions
BOLT ownershipBolt Biotherapeutics, Inc. (BOLT) is primarily owned by institutional investors, who hold approximately 41.8% of shares. The largest shareholder is VIVO CAPITAL, LLC with a 9.18% stake. Company insiders hold 18.39%. Data sourced from SEC Form 13F as of September 30, 2025.